Mountain Valley MD is committed to redefining the limits of what is believed possible when delivering beneficial molecules into the body. We are working on infusing our delivery technology across a diverse product family, ranging from nutraceuticals through to advanced pharmaceutical drugs.
We are working with advanced desiccated liposome formulations and our related international patents for advanced compressible delivery formulations for transmucosal delivery. Our proposition for delivering formulations that have rapid onset, with high bioavailability, with precision dosing technology will be core to our success across leading application categories.
We are working with advanced desiccated liposome formulations across our international patent portfolio with advanced compressible delivery formulations for transmucosal delivery. Our proposition for delivering formulations that have rapid onset, with high bioavailability, and precision dosing technology will be core to our success across leading health and wellness application categories.
MVMD products that are developed for our commercial partners will be branded with our trademarked Quicksome™ logo to differentiate and effectively position MVMD’s technology at the retail consumer level.
Mountain Valley MD's research and development lab work is focused on delivery technologies that have rapid absorption and increased bioavailability in an unprecedented way. Our advanced pursuit of clinical evidence is core to our business strategy for broad consumer adoption and key pharmaceutical licensing agreements.
Following encouraging results from rounds of internal testing on both product prototypes, MVMD is moving forward to undertake:
Human proof of concept pharmacokinetic studies for the pain sublingual thin strip product.
Diabetes canine trials for the insulin sublingual thin strip product.
The goal of these studies is to compare the pain and insulin thin strip products against potentially competing products already on the market, in an effort to demonstrate superior onset and bioavailability, consistent with our internal trials.
MVMD's thin strip pain product is being tested and compared to Sativex® as the benchmark delivery platform against which to test the pharmacokinetics of MVMD’s strip delivery technology.
Sativex® is a cannabis-based oral-mucosal spray containing delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Sativex® is approved for the relief of multiple sclerosis (MS) symptoms in the United States and the treatment of cancer pain in Canada. The sublingual pain thin strip testing protocol aims to validate MVMD’s internal testing results and belief that this product has a higher bioavailability and reduced time of onset than Sativex®.
The trial will employ a double-blind crossover to compare the Tmax, Cmax and AUC of the pain product against Sativex®.
The sublingual insulin thin strip product testing and canine trial will aim to demonstrate the bioequivalence of MVMD’s sublingual insulin delivery system along with a faster onset versus current needle injection, offering patients an ease of administration and rapid onset when compared to leading injection insulin products.
View all MVMD media releases. Subscribe below to stay updated.Learn More